Michael A. Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 15,628 shares at $15.05 ($235K) on 2025-03-04, disclosed to the SEC on 2025-03-06.
Scheduled sale ($235k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.05 | 7,814 | $118K | 50.0% |
| 2 | $15.05 | 7,814 | $118K | 50.0% |
| Total | $15.05 avg | 15,628 | $235K | 100% |
| Filing → |
| SNDX | SELL | 2026-02-10 | $361K | — | Filing → |
| SNDX | SELL | 2026-02-06 | $153K | — | Filing → |
| SNDX | SELL | 2025-09-08 | $5.2M | — | Filing → |